First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
Clinical trial NCT04725474 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04725474
- Sponsor
- CatalYm GmbH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-09
- Primary completion
- 2028-04-30
- Enrollment
- 263
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.